Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 5, 2011, Pages 695-703

  El btaouri, Hassan ^a   Morjani, Hamid ^a   Greffe, Yannick ^a   Charpentier, Emmanuelle ^a   Martiny, Laurent ^a  

^a CNRS   (France)

Author keywords

ATF 2; Cancer; Ceramide; Extracellular matrix; JNK; Thrombospondin

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BETA ACTIN; CAMPTOTHECIN; CERAMIDE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; THROMBOSPONDIN 1;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

ACTIVATING TRANSCRIPTION FACTOR 2; ANTHRACENES; APOPTOSIS; CAMPTOTHECIN; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPHINGOSINE; THROMBOSPONDIN 1; THYROID NEOPLASMS;

EID: 79955664110     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.02.004     Document Type: Article

References (57)

1. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 2000, 6:41-48.
2. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 2001, 17:25-51.
3. Savill J., Hogg N., Ren Y., Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J. Clin. Invest. 1992, 90:1513-1522.
4. Sipes J.M., Krutzsch H.C., Lawler J., Roberts D.D. Cooperation between thrombospondin-1 type 1 repeat peptides and alpha(v)beta(3) integrin ligands to promote melanoma cell spreading and focal adhesion kinase phosphorylation. J. Biol. Chem. 1999, 274:22755-22762.
5. Rath G.M., Schneider C., Dedieu S., Rothhut B., Soula-Rothhut M., Ghoneim C., Sid B., Morjani H., El Btaouri H., Martiny L. The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochim. Biophys. Acta 2006, 1763:1125-1134.
6. Rath G., Schneider C., Langlois B., Sartelet H., Morjani H., Btaouri H.E., Dedieu S., Martiny L. De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. Int. J. Biochem. Cell Biol. 2009, 41:1165-1172.
7. Blatt N.B., Glick G.D. Signaling pathways and effector mechanisms pre-programmed cell death. Bioorg. Med. Chem. 2001, 9:1371-1384.
8. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 1999, 79:143-180.
9. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 1999, 18:6087-6093.
10. Wang L.H., Besirli C.G., Johnson E.M. Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 2004, 44:451-474.
11. Pena L.A., Fuks Z., Kolesnick R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem. Pharmacol. 1997, 53:615-621.
12. Enomoto A., Suzuki N., Hirano K., Matsumoto Y., Morita A., Sakai K., Koyama H. Involvement of SAPK/JNK pathway in X-ray-induced rapid cell death of human T-cell leukemia cell line MOLT-4. Cancer Lett. 2000, 155:137-144.
13. Oh H.L., Seok J.Y., Kwon C.H., Kang S.K., Kim Y.K. Role of MAPK in ceramide-induced cell death in primary cultured astrocytes from mouse embryonic brain. Neurotoxicology 2006, 27:31-38.
14. Selimovic D., Hassan M., Haikel Y., Hengge U.R. Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cell. Signal. 2008, 20:311-322.
15. Kim J., Kim C., Kim T.S., Bang S.I., Yang Y., Park H., Cho D. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem. Biophys. Res. Commun. 2006, 344:1284-1289.
16. Goretzki P.E., Frilling A., Simon D., Roeher H.D. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res. 1990, 118:48-63.
17. Guillemot L., Levy A., Raymondjean M., Rothhut B. Angiotensin II-induced transcriptional activation of the cyclin D1 gene is mediated by Egr-1 in CHO-AT(1A) cells. J. Biol. Chem. 2001, 276:39394-39403.
18. Lin A., Dibling B. The true face of JNK activation in apoptosis. Aging Cell 2002, 1:112-116.
19. Liu J., Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res. 2005, 15:36-42.
20. Gupta S., Campbell D., Derijard B., Davis R.J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995, 267:389-393.
21. Persengiev S.P., Green M.R. The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis 2003, 8:225-228.
22. Hogg P.J., Owensby D.A., Mosher D.F., Misenheimer T.M., Chesterman C.N. Thrombospondin is a tight-binding competitive inhibitor of neutrophil elastase. J. Biol. Chem. 1993, 268:7139-7146.
23. Morandi V., Cherradi S.E., Lambert S., Fauvel-Lafeve F., Legrand Y.J., Legrand C. Proinflammatory cytokines (interleukin-1 beta and tumor necrosis factor-alpha) down regulate synthesis and secretion of thrombospondin by human endothelial cells. J. Cell. Physiol. 1994, 160:367-377.
24. Loganadane L.D., Berge N., Legrand C., Fauvel-Lafeve F. Endothelial cell proliferation regulated by cytokines modulates thrombospondin-1 secretion into the subendothelium. Cytokine 1997, 9:740-746.
25. Verheij M., Bose R., Lin X.H., Yao B., Jarvis W.D., Grant S., Birrer M.J., Szabo E., Zon L.I., Kyriakis J.M., Haimovitz-Friedman A., Fuks Z., Kolesnick R.N. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996, 380:75-79.
26. Sumbayev V.V., Yasinska I.M. Role of MAP kinase-dependent apoptotic pathway in innate immune responses and viral infection. Scand. J. Immunol. 2006, 63:391-400.
27. Verheij M., Ruiter G.A., Zerp S.F., van Blitterswijk W.J., Fuks Z., Haimovitz-Friedman A., Bartelink H. The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-induced apoptosis. Radiother. Oncol. 1998, 47:225-232.
28. Chovolou Y., Watjen W., Kampkotter A., Kahl R. Downregulation of NF-kappaB activation in a H4IIE transfectant insensitive to doxorubicin-induced apoptosis. Toxicology 2007, 232:89-98.
29. Min B.W., Kim C.G., Ko J., Lim Y., Lee Y.H., Shin S.Y. Transcription of the protein kinase C-delta gene is activated by JNK through c-Jun and ATF2 in response to the anticancer agent doxorubicin. Exp. Mol. Med. 2008, 40:699-708.
30. Noutomi T., Itoh M., Toyota H., Takada E., Mizuguchi J. Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells. Oncol. Rep. 2009, 22:1169-1172.
31. Tournier C., Hess P., Yang D.D., Xu J., Turner T.K., Nimnual A., Bar-Sagi D., Jones S.N., Flavell R.A., Davis R.J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000, 288:870-874.
32. Sengupta K., Banerjee S., Saxena N.K., Banerjee S.K. Thombospondin-1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression is suppressed by estradiol. Mol. Cancer Res. 2004, 2:150-158.
33. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252.
34. Bulgin D., Podtcheko A., Takakura S., Mitsutake N., Namba H., Saenko V., Ohtsuru A., Rogounovitch T., Palona I., Yamashita S. Selective pharmacologic inhibition of c-Jun NH2-terminal kinase radiosensitizes thyroid anaplastic cancer cell lines via induction of terminal growth arrest. Thyroid 2006, 16:217-224.
35. Potapova O., Haghighi A., Bost F., Liu C., Birrer M.J., Gjerset R., Mercola D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 1997, 272:14041-14044.
36. Gjerset R.A., Lebedeva S., Haghighi A., Turla S.T., Mercola D. Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification. Cell Growth Differ. 1999, 10:545-554.
37. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., Jikihara H., Mercola D., Murata Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 1999, 274:31648-31654.
38. Janes K.A., Albeck J.G., Gaudet S., Sorger P.K., Lauffenburger D.A., Yaffe M.B. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 2005, 310:1646-1653.
39. Sanchez-Perez I., Murguia J.R., Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998, 16:533-540.
40. Chen Y.R., Tan T.H. The c-Jun N-terminal kinase pathway and apoptotic signaling. Int. J. Oncol. 2000, 16:651-662.
41. Han J., Sun P. The pathways to tumor suppression via route p38. Trends Biochem. Sci. 2007, 32:364-371.
42. Hui L., Bakiri L., Stepniak E., Wagner E.F. p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 2007, 6:2429-2433.
43. Thornton T.M., Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int. J. Biol. Sci. 2009, 5:44-51.
44. Saavedra A.P., Tsygankova O.M., Prendergast G.V., Dworet J.H., Cheng G., Meinkoth J.L. Role of cAMP, PKA and Rap1A in thyroid follicular cell survival. Oncogene 2002, 21:778-788.
45. El Btaouri H., Rath G., Morjani H., Schneider C., Petitfrere E., Antonicelli F., Martiny L. Interleukin-1beta-induced apoptosis through adenylyl cyclase and ERK1/2 inhibition in primary cultured thyroid cells. Biochem. Biophys. Res. Commun. 2006, 339:469-476.
46. Engel I., Murre C. The function of E- and Id proteins in lymphocyte development. Nat. Rev. Immunol. 2001, 1:193-199.
47. Hasskarl J., Munger K. Id proteins-tumor markers or oncogenes?. Cancer Biol. Ther. 2002, 1:91-96.
48. Hickman E.S., Moroni M.C., Helin K. The role of p53 and pRB in apoptosis and cancer. Curr. Opin. Genet. Dev. 2002, 12:60-66.
49. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
50. Zhang H.S., Postigo A.A., Dean D.C. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999, 97:53-61.
51. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
52. Morrison D.K., Davis R.J. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 2003, 19:91-118.
53. Gueorguiev V.D., Cheng S.Y., Sabban E.L. Prolonged activation of cAMP-response element-binding protein and ATF-2 needed for nicotine-triggered elevation of tyrosine hydroxylase gene transcription in PC12 cells. J. Biol. Chem. 2006, 281:10188-10195.
54. Vlahopoulos S.A., Logotheti S., Mikas D., Giarika A., Gorgoulis V., Zoumpourlis V. The role of ATF-2 in oncogenesis. Bioessays 2008, 30:314-327.
55. Vacotto M., Coso O., Fiszer de Plazas S. Programmed cell death and differential JNK, p38 and ERK response in a prenatal acute hypoxic hypoxia model. Neurochem. Int. 2008, 52:857-863.
56. Soula-Rothhut M., Coissard C., Sartelet H., Boudot C., Bellon G., Martiny L., Rothhut B. The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Exp. Cell Res. 2005, 304:187-201.
57. Sherman S.I. Targeted therapy of thyroid cancer. Biochem. Pharmacol. 2010, 80:592-601.